Sharon A Riddler1, Marla Husnik2, Pamina M Gorbach3, Lisa Levy4, Urvi Parikh1, Edward Livant5, Arendevi Pather6, Bonus Makanani7, Felix Muhlanga8, Margaret Kasaro9, Francis Martinson10, Vanessa Elharrar11, Jennifer E Balkus2. 1. a Division of Infectious Diseases , University of Pittsburgh , Pittsburgh , PA , USA. 2. b MTN Statistical and Data Management Center , Fred Hutchinson Cancer Research Center , Seattle , WA , USA. 3. c Department of Epidemiology , University of California , Los Angeles , CA , USA. 4. d FHI360 , Durham, NC , USA. 5. e Microbicide Trials Network , Magee-Womens Research Institute , Pittsburgh , PA , USA. 6. f HIV Prevention Research Unit , South African Medical Research Council , Durban , South Africa. 7. g College of Medicine-John Hopkins University Research Project , Queen Elizabeth Central Hospital , Blantyre , Malawi. 8. h UZ-UCSF Collaborative Research Programme , University of Zimbabwe , Harare , Zimbabwe. 9. i Centre for Infectious Disease Research in Zambia , Lusaka , Zambia. 10. j UNC Project - Tidziwe Centre , Kamuzu Central Hospital , Lilongwe , Malawi. 11. k Division of AIDS , National Institutes of Health , Bethesda , MD , USA.
Abstract
BACKGROUND: As the effect of biomedical prevention interventions on the natural history of HIV-1 infection in participants who seroconvert is unknown, the Microbicide Trials Network (MTN) established a longitudinal study (MTN-015) to monitor virologic, immunological, and clinical outcomes, as well as behavioral changes among women who become HIV-infected during MTN trials. We describe the rationale, study design, implementation, and enrollment of the initial group of participants in the MTN seroconverter cohort. METHODS: Initiated in 2008, MTN-015 is an ongoing observational cohort study enrolling participants who acquire HIV-1 infection during effectiveness studies of candidate microbicides. Eligible participants from recently completed and ongoing MTN trials are enrolled after seroconversion and return for regular follow-up visits with clinical and behavioral data collection. Biologic samples including blood and genital fluids are stored for future testing. RESULTS: MTN-015 was implemented initially at six African sites and enrolled 100/139 (72%) of eligible women who seroconverted in HIV Prevention Trials Network protocol 035 (HPTN 035, conducted by the MTN). The median time from seroconversion in HPTN 035 to enrollment in MTN-015 was 18 months. Retention was good with >70% of visits completed. Implementation challenges included regulatory reviews, translation, and testing of questionnaires, and site readiness. CONCLUSIONS: Enrollment of HIV-seroconverters into a longitudinal observational follow-up study is feasible and acceptable to participants. Data and samples collected in this protocol will be used to assess safety of investigational HIV microbicides and answer other important public health questions for HIV infected women.
BACKGROUND: As the effect of biomedical prevention interventions on the natural history of HIV-1 infection in participants who seroconvert is unknown, the Microbicide Trials Network (MTN) established a longitudinal study (MTN-015) to monitor virologic, immunological, and clinical outcomes, as well as behavioral changes among women who become HIV-infected during MTN trials. We describe the rationale, study design, implementation, and enrollment of the initial group of participants in the MTN seroconverter cohort. METHODS: Initiated in 2008, MTN-015 is an ongoing observational cohort study enrolling participants who acquire HIV-1 infection during effectiveness studies of candidate microbicides. Eligible participants from recently completed and ongoing MTN trials are enrolled after seroconversion and return for regular follow-up visits with clinical and behavioral data collection. Biologic samples including blood and genital fluids are stored for future testing. RESULTS:MTN-015 was implemented initially at six African sites and enrolled 100/139 (72%) of eligible women who seroconverted in HIV Prevention Trials Network protocol 035 (HPTN 035, conducted by the MTN). The median time from seroconversion in HPTN 035 to enrollment in MTN-015 was 18 months. Retention was good with >70% of visits completed. Implementation challenges included regulatory reviews, translation, and testing of questionnaires, and site readiness. CONCLUSIONS: Enrollment of HIV-seroconverters into a longitudinal observational follow-up study is feasible and acceptable to participants. Data and samples collected in this protocol will be used to assess safety of investigational HIV microbicides and answer other important public health questions for HIV infectedwomen.
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Salim S Abdool Karim; Barbra A Richardson; Gita Ramjee; Irving F Hoffman; Zvavahera M Chirenje; Taha Taha; Muzala Kapina; Lisa Maslankowski; Anne Coletti; Albert Profy; Thomas R Moench; Estelle Piwowar-Manning; Benoît Mâsse; Sharon L Hillier; Lydia Soto-Torres Journal: AIDS Date: 2011-04-24 Impact factor: 4.177
Authors: Teri Liegler; Mohamed Abdel-Mohsen; L Gordon Bentley; Robert Atchison; Timothy Schmidt; Jacqueline Javier; Megha Mehrotra; Christopher Eden; David V Glidden; Vanessa McMahan; Peter L Anderson; Peilin Li; Joseph K Wong; Susan Buchbinder; Juan V Guanira; Robert M Grant Journal: J Infect Dis Date: 2014-04-16 Impact factor: 5.226
Authors: Margaret R Caplan; Raphael J Landovitz; Thesla Palanee-Phillips; Gonasagrie Nair; Felix Mhlanga; Jennifer E Balkus; Sharon A Riddler; Pamina M Gorbach Journal: AIDS Care Date: 2019-02-13
Authors: Dvora L Joseph Davey; Linda-Gail Bekker; Elizabeth A Bukusi; Benjamin H Chi; Sinead Delany-Moretlwe; Ameena Goga; Anne Drapkin Lyerly; Nyaradzo M Mgodi; Nelly Mugo; Landon Myer; Lisa M Noguchi; Lynda Stranix-Chibanda; Catherine Slack; Jillian Pintye Journal: Lancet HIV Date: 2022-01-25 Impact factor: 16.070
Authors: Sharon A Riddler; Jennifer E Balkus; Urvi M Parikh; John W Mellors; Carolyne Akello; Sufia Dadabhai; Felix Mhlanga; Gita Ramjee; Ashley J Mayo; Edward Livant; Amy L Heaps; Colin O'Rourke; Jared M Baeten Journal: Clin Infect Dis Date: 2019-07-18 Impact factor: 9.079
Authors: Elizabeth T Montgomery; Sarah T Roberts; Annalene Nel; Mariette Malherbe; Kristine Torjesen; Katherine Bunge; Devika Singh; Jared M Baeten; Jeanne Marrazzo; Z Mike Chirenje; Samuel Kabwigu; Richard Beigi; Sharon A Riddler; Zakir Gaffour; Krishnaveni Reddy; Leila E Mansoor; Gonasagrie Nair; Kusbashni Woeber; Jayajothi Moodley; Nitesha Jeenarain; Samantha Siva; Logashvari Naidoo; Vaneshree Govender; Thesla Palanee-Phillips Journal: AIDS Date: 2019-11-15 Impact factor: 4.177